Pasithea therapeutics corp. announces pricing of a $30.4 million private placement priced at a premium to the market under nasdaq rules

Miami beach, fla., nov. 24, 2021 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta; kttaw) (“pasithea” or the “company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, at a purchase price of $3.50 per share and accompanying warrant in a private placement priced at a premium to the market under nasdaq rules. the gross proceeds to the company from the private placement are expected to be approximately $30.4 million before deducting the placement agent's fees and other estimated offering expenses.
KTTA Ratings Summary
KTTA Quant Ranking